NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $1.42 +0.07 (+5.04%) Closing price 04/25/2025 04:10 PM EasternExtended Trading$1.41 -0.01 (-0.70%) As of 04/25/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.38▼$1.4250-Day Range N/A52-Week Range$0.90▼$3.45Volume4,666 shsAverage Volume11,678 shsMarket Capitalization$51.38 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Read More… Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreARMP MarketRank™: Armata Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArmata Pharmaceuticals has received no research coverage in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Armata Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News SentimentArmata Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for ARMP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Stock News HeadlinesArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deArmata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last yearMarch 21, 2025 | markets.businessinsider.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 26, 2025 | Porter & Company (Ad)Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 20, 2025 | prnewswire.comArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with InnovivaMarch 12, 2025 | prnewswire.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy SummitMarch 11, 2025 | prnewswire.comPromising Phase 2 Results for AP-PA02 Boost Armata Pharmaceuticals’ Investment AppealDecember 22, 2024 | markets.businessinsider.comArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 studyDecember 20, 2024 | finance.yahoo.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $2.00 on January 1st, 2025. Since then, ARMP stock has decreased by 29.0% and is now trading at $1.42. View the best growth stocks for 2025 here. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) posted its earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The business had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.90 million. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN). Company Calendar Last Earnings11/14/2023Today4/26/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+393.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net MarginsN/A Pretax Margin-756.59% Return on EquityN/A Return on Assets-60.91% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual Sales$4.53 million Price / Sales11.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.89) per share Price / Book-1.60Miscellaneous Outstanding Shares36,180,000Free Float5,247,000Market Cap$51.38 million OptionableNot Optionable Beta0.87 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.